ResearcherSeoul National UniversityNo recent work listed
Hyoung Woo Kim
Matched on ORCID iD 0000-0002-5135-7355; OpenAlex author ID A5100686276. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: 1 paper
Papers 7
- Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. Co-author DOI 10.1371/journal.pone.0238649↗
- It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2018.08.002↗
- Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Co-author DOI 10.1097/md.0000000000013592↗
- Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Co-author DOI 10.1016/j.ejca.2017.02.010↗
- Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.12.038↗
- Early versus delayed initiation of adjuvant treatment for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0173960↗
- MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer. Co-author DOI 10.4166/kjg.2015.66.4.215↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jin‐Hyeok Hwang · 7 shared papers, 2015–2020 · strength 0.65
- Paper Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. DOI 10.1371/journal.pone.0238649↗
- Paper Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. DOI 10.1097/md.0000000000013592↗
- Paper It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. DOI 10.1016/j.hbpd.2018.08.002↗
- Jaihwan Kim · 6 shared papers, 2017–2020 · strength 0.58
- Paper Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. DOI 10.1371/journal.pone.0238649↗
- Paper Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. DOI 10.1097/md.0000000000013592↗
- Paper It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. DOI 10.1016/j.hbpd.2018.08.002↗
- Jong-chan Lee · 3 shared papers, 2017–2020 · strength 0.35
- Paper Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. DOI 10.1371/journal.pone.0238649↗
- Paper Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. DOI 10.1097/md.0000000000013592↗
- Paper Early versus delayed initiation of adjuvant treatment for pancreatic cancer. DOI 10.1371/journal.pone.0173960↗
- Jong-Chan Lee · 3 shared papers, 2017–2018 · strength 0.23
- Paper It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. DOI 10.1016/j.hbpd.2018.08.002↗
- Paper Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative rel… DOI 10.1016/j.ejca.2017.02.010↗
- Paper Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. DOI 10.1016/j.surg.2016.12.038↗
- Jin Won Kim · 2 shared papers, 2017 · strength 0.16
- Young Hoon Kim · 2 shared papers, 2017 · strength 0.14
- Paper Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative rel… DOI 10.1016/j.ejca.2017.02.010↗
- Paper Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. DOI 10.1016/j.surg.2016.12.038↗
- Haeryoung Kim · 1 shared paper, 2018 · strength 0.09
- Yoo‐Seok Yoon · 1 shared paper, 2017 · strength 0.07
- Ho‐Seong Han · 1 shared paper, 2017 · strength 0.07
- Woo Hyun Paik · 1 shared paper, 2015 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.